- Open Access
A novel HIV-1 restriction factor that is biologically distinct from APOBEC3 cytidine deaminases in a human T cell line CEM.NKR
© Zhou et al; licensee BioMed Central Ltd. 2009
- Received: 12 January 2009
- Accepted: 03 April 2009
- Published: 03 April 2009
Isolation of novel retroviral restriction factors will open new avenues for anti-HIV/AIDS treatment. Although HIV-1 replication is restricted by APOBEC3G/APOBEC3F, TRIM5α, and CD317, none defend HIV-1 infection under natural conditions. Previously, we demonstrated a host factor from the human T cell line CEM.NKR that potently restricted wild-type HIV-1 replication. Interestingly, this restriction resembled the APOBEC3G/APOBEC3F pattern in that viral replication was inhibited from the second round of replication cycle at a post-entry step.
Here, we further characterized this factor and found it distinguishable from the known anti-HIV APOBEC3 proteins. Although CEM.NKR cells expressed both APOBEC3G and APOBEC3F, their levels were at least 10 or 4-fold lower than those in H9 cells, and importantly, Vif effectively neutralized their activity. Among eight subclones isolated from CEM.NKR cells, one was relatively permissive, four were semi-permissive, and three were completely non-permissive for HIV-1 replication. When the levels of APOBEC3 expression were determined, all these clones retained similar low levels of APOBEC3DE, APOBEC3F, APOBEC3G and APOBEC3H expression, and no APOBEC3B expression was detected. Since the vif from SIVmac can effectively neutralize APOBEC3B and APOBEC3H, recombinant HIV-1 expressing this SIV gene were created. However, these viruses still failed to replicate in CEM.NKR cells. We also confirmed that HIV-1 restriction in CEM.NKR was not due to a loss of calnexin expression.
Taken together, these results not only demonstrate that all these aforementioned anti-HIV APOBEC3 proteins do not contribute to this HIV-1 restriction, but also shed light on a novel and potent HIV-1 inhibitor in CEM.NKR cells.
- Green Fluorescence Protein
- Infectious Particle
- Fusion Efficiency
- APOBEC3 Protein
- APOBEC3 Expression
CEM is a human T lymphosarcoma cell line isolated from an infant female patient with acute leukemia . This human T cell line has been useful in HIV research because of its infectability and has significantly contributed to our understanding of innate intracellular immunity to retroviruses. Human T cell lines have been classified as either permissive or non-permissive cells based on their ability to support vif-deficient HIV-1 replication. CEM and H9 are non-permissive cell lines, whereas Sup-T1 and Jurkat are permissive lines [2, 3]. Derivative cell lines have been isolated from CEM by various methods, including CEM-SS , CEM-T4, A3.01 , and CEM.NKR . Interestingly, both CEM-SS and CEM-T4 are permissive for vif-deficient HIV-1 replication whereas A3.01 is semi-permissive , suggesting that the original CEM cells are quite heterogeneous. Importantly, genetic analysis of the difference between CEM and CEM-SS has led to the discovery of APOBEC3G (A3G) as one of the cellular targets of Vif .
A3G belongs to a small group of proteins in the cytidine deaminase family known as the APOBEC3 (A3) subfamily . This group of proteins includes A3A, A3B, A3C, A3DE, A3F, A3G, and A3H. All have antiretroviral activities against different targets including exogenous retroviruses and endogenous retroelements . A3B, A3DE, A3F, and A3G contain two Zinc-binding motifs, while A3A, A3C, and A3H contain only one. A3B, A3DE, A3F, and A3G inhibit HIV-1 replication to different degrees, whereas A3A and A3C do not [8, 11–16]. Recently, it was shown that A3H also inhibits HIV-1 replication if its expression is optimized in cell culture [17–20]. Among these proteins, the anti-HIV activity of A3G and A3F is the most prominent. Nevertheless, HIV-1 is able to elude this defense mechanism and cause human disease for two reasons. First, A3B and A3H are poorly expressed in vivo [13, 17, 21, 22]. Second, HIV-1 produces Vif, which binds to and mediates the destruction of A3DE, A3F, and A3G in 26S proteasomes via recruitment of the Cullin5 ubiquitin E3 ligase [23, 24]. Vif may also inhibit A3 activity independent of proteasomal degradation [25–27]. In addition to Vif activity, HIV-1 replication can also be inhibited by two other types of restriction factors: TRIM5α which blocks viral uncoating  and cell surface protein CD317 which blocks viral release . However, human TRIM5a does not inhibit HIV-1, and the antiviral activity of CD317 is neutralized by another viral protein Vpu.
CEM.NKR is a naturally isolated cell clone from CEM that is resistant to natural killer (NK) cell-mediated lysis . Previously, we tried to infect CEM.NKR cells and found that they were highly resistant to productive infection by wild-type HIV-1 . Further analyses indicated that CEM.NKR expressed a viral inhibitor, which did not target incoming viruses but blocked HIV-1 at the second round of replication at a post-entry step. Since this inhibitor showed a similar inhibition profile as A3G/A3F except that it inhibited the wild-type virus, we wondered whether this resistance was simply due to an over-expression or expression of a genetic variant of known A3 cytidine deaminases which could not be inhibited by Vif. Here, we present several different lines of evidence to demonstrate that this inhibitor activity is indeed novel and distinguishable from any of A3 proteins.
Over-expression of A3G/A3F is not responsible for wild-type HIV-1 restriction in human T cells
Second, we compared A3G/A3F protein levels in H9 and CEM.NKR cells to determine whether A3G/A3F were overly expressed in CEM.NKR cells. Cell lysates were prepared from a total of 1 × 107 H9 or CEM.NKR cells. Two-fold serial dilutions were analyzed by Western blotting using A3G or A3F-specific antibody. Actin served as a loading control. Surprisingly, the levels of both A3G and A3F in CEM.NKR cells were around 10 or 4-fold lower than those in H9 cells, respectively (Fig. 1B). This result indicated that restriction of HIV-1 replication in CEM.NKR was not due to over-expression of A3G and A3F. We next determined whether A3G or A3F genes contained mutations that would reduce their sensitivity to Vif and contribute to the HIV-1 non-permissiveness in CEM.NKR. A3G and A3F cDNAs were amplified from CEM.NKR by RT-PCR and cloned for sequencing. Interestingly, it was found that the A3G gene contained a R14Q and A3F contained a Q275E mutation. To test how these mutations affected A3G and A3F, these genes were cloned into pcDNA3.1 assayed for their effect on HIV-1 in a single round replication cycle. Wild-type and vif-deficient HIV-1 luciferase reporter viruses were produced from 293T cells in the presence of the wild-type or mutant A3G or A3F expression vectors. Equal amounts of viruses were collected to infect GHOST cells and viral infectivity was determined by measuring cellular luciferase activities. Compared to the infectivity of the control HIV-1 produced in the absence of any A3G/A3F proteins, all A3G and A3F proteins (wild-type and mutants) reduced the HIV-1ΔVif virus infectivity significantly more than HIV-1 virus infectivity (Fig. 1C). For example, A3G, A3G R14Q, A3F, or A3F Q275E reduced HIV-1 infectivity by 12, 8, 60, or 16-fold and HIV-1ΔVif infectivity by 260, 60, 270, or 80-fold respectively. Although these results might indicate that A3G R14Q and A3F Q275E had slightly lower anti-HIV-1 activity, these proteins were still sensitive to Vif.
Third, we wanted to directly demonstrate that Vif could neutralize A3G/A3F in CEM.NKR cells. Our strategy was to create HIV-1 and HIV-1ΔVif virus-infected CEM.NKR cells and compare levels of G-to-A mutations in HIV-1 genomes. If the HIV-1 contained lower levels of mutations than the HIV-1ΔVif, it should further confirm A3G/A3F sensitivity to Vif. Since CEM.NKR cells were very difficult to infect, they were infected with HIV-1 or HIV-1ΔVif viruses expressing a neomycin-resistance gene (pNL-Neo, pNL-NeoΔVif) and infected cells were amplified by G418 treatment. As controls, H9 cells were infected and treated similarly. After that, cellular DNAs were extracted and HIV genes were amplified by PCR and cloned into a T-A cloning vector for sequencing. It was found that all viral genomes contained much higher rates of G-to-A of mutations than any other mutations (Fig. 1D). Further analyses found that these excessive G-to-A mutations occurred in both GG and GA dinucleotides (data not shown), which are preferred mutation sites for A3G and A3F. In addition, the G-to-A hypermutation rate was much higher in H9 than CEM.NKR cells, which was consistent with the higher A3G/A3F expression levels in H9 cells. Moreover, when Vif was present, this G-to-A hypermutation rate was reduced to half in both H9 and CEM.NKR cells (Fig. 1D). These results clearly indicated that Vif could neutralize A3G/A3F activity in CEM.NKR cells as efficiently as in H9 cells, and they also pointed out that a complete elimination of their activities by Vif might not be possible in these human T cells. Thus, we concluded that HIV-1 resistance in CEM.NKR was not due to the inability of Vif to neutralize A3G/A3F.
Analysis of HIV-1 resistance in CEM.NKR subpopulations
Lack of correlation of A3 expression with HIV-1 replication in CEM.NKR cell clones
Calnexin does not rescue HIV-1 replication in CEM.NKR cells
CEM.NKR cells express a HIV-1 inhibitor
Previously, we demonstrated that CEM.NKR cells expressed a HIV-1 inhibitor using a cell fusion assay . In this assay, 293T cells expressing HIV-1 gp160 were co-cultured with CEM.NKR cells producing env-defective HIV-1. Only heterokaryons formed by gp160 and CD4/CXCR4 mediated cell fusion could release infectious particles, which could be detected by infection of the HIV indicator cell line TZM-BI. The levels of infectious particles from heterokaryons should positively correlate with HIV-1 resistance of the tested cell line. Notably, the levels of infectious particles from heterokaryons should also positively correlate with the fusion efficiency between 293T and the target T cells. We therefore assessed the fusion efficiency of 293T with CEM.NKR as well as its subclones.
We next determined the levels of infectious particles produced from these co-cultures. A2.01 cells were used as a negative control because this cell line did not express CD4 and could not fuse with 293T cells expressing gp160 . Indeed, co-cultures of 293T with A2.01, CEM.NKR, clone #2, and clone #5 all produced very low levels of infectious particles, whereas the co-culture of 293T with CEM-SS produced 10 to 20-fold more infectious particles (Fig. 5B). These results indicated that poor production of infectious particles from co-cultures of 293T with CEM.NKR and its subclones was not due to the poor fusion efficiency, and instead, it was due to the presence of an HIV-1 inhibitor.
To further confirm these observations, we tried to directly fuse these CEM.NKR clones with CEM-SS cells to see whether viral production could be suppressed. It is known that T-cell tropic HIV-1 can induce cell fusion and cause syncytium-formation during infection. CEM-SS cell line is not only highly permissive for HIV-1 infection, but also sensitive to HIV-1-induced syncytium-formation . Thus, fusion between CEM-SS and CEM.NKR cells could occur naturally if they were co-cultured during HIV-1 infection. In addition, we tired to further increase this fusion efficiency by treating cells with polyethylene glycol (PEG).
Although clone #5 was the most permissive for HIV-1 infection among the CEM.NKR clones, we found that this cell line was still much less permissive than CEM-SS (Fig. 5C). Thus, this cell line might still express the same HIV-1 inhibitor, albeit at a decreased level. We therefore used both clone #5 and #2 for this determination. HIV-1-infected CEM-SS, CEM.NKR, clone #5, or clone #2 cells were co-cultured with or without a brief PEG treatment and viral production was determined over a 10-day period. Even without PEG treatment, levels of virus production were all reduced from CEM-SS+CEM.NKR, CEM-SS+clone #5, and CEM-SS+clone #2 co-cultures, and importantly, the reduction from CEM-SS+clone #2 was much more significant (Fig. 5D). Since we already demonstrated that CEM.NKR cells did not secrete a soluble HIV-1 inhibitor (Fig. 1A), such reduction could be explained by the appearance of cell fusion of CEM-SS with CEM.NKR, clone #5, and clone #2 cells, resulting in an inhibition of HIV-1 replication. When treated with PEG, viral production was further reduced, which could be due to an increase in cell fusion efficiency (Fig. 5D). These results not only further supported our previous conclusion that CEM.NKR cells expressed a HIV-1 inhibitor, but also indicated that clone #5 could express relatively lower levels of this inhibitor than clone #2.
The replication of HIV-1 expressing viffrom SIVmac is still restricted in CEM.NKR cells
It is known that vif from HIV-1 does not neutralize human A3B and A3H [11, 17]. However, vif from SIVmac neutralizes not only human A3DE, A3F, and A3G, but also human A3B and A3H [11, 12, 17, 34–36]. These observations suggest that vif from SIVmac is a powerful tool to knock down all these known anti-HIV human APOBEC3 proteins. Although we already knew that CEM.NKR cells had low levels of A3B and A3H expression (Fig. 3C), we wanted to further exclude that they were not responsible for HIV-1 restriction in CEM.NKR cells.
Next, we used viruses produced from pNL-macVif to infect several different human T cell lines. In a 16-day period, these viruses replicated robustly in both CEM-SS cells and CEM-SS cells expressing an exogenous A3G gene, indicating that they successfully overcame A3G restriction; they replicated well in H9 cells, indicating that they could also overcome A3F and A3DE restriction (Fig. 6B). Notably, their replications in CEM.NKR cell line as well as its clones #5 and #2 were quite similar to the wild-type HIV-1 as seen in Fig. 2B. The relatively permissive clone #5 also supported pNL-macVif viruses replication whereas the non-permissive clone #2 did not. The parental CEM.NKR cell line showed a phenotype between these two clones. These results demonstrated that HIV-1 replication was still restricted in CEM.NKR cells even in the presence of vif from SIVmac, which disproved any possible role of A3B and A3H in this HIV-1 restriction.
In this report, we have not only confirmed the HIV-1 inhibitor in CEM.NKR cells, but also found that it was quite different from any known APOBEC3 proteins. Although CEM.NKR cells expressed A3G and A3F, their activities were effectively neutralized by HIV-1 Vif as evidenced by the decreased G-to-A hypermutations in the wild-type viral genome (Fig. 1D). They, therefore, should not be able to restrict the wild-type HIV-1 replication in CEM.NKR cells. In addition, we found that both A3B and A3H were poorly expressed in CEM.NKR cells (Fig. 3C and data not shown), and importantly, HIV-1 expressing vif from SIVmac that effectively inactivated theses two human genes still failed to productively replicate in these cells (Fig. 6B). These results excluded any possible contribution of these APOBEC3 cytidine deaminases to this restriction. Thus, CEM.NKR cells express a novel host factor that potently inhibit HIV-1 replication.
So far, all biologically functional retrovirus restriction factors identified in humans, including A3G/A3F [8, 15, 16], TRIM5α , and CD317 , have been counteracted by HIV-1. The A3G/A3F proteins are targeted for proteasomal degradation by Vif [15, 16, 24, 37–39]; the CD317 proteins that can tether viral particles on the cell surface are inactivated by Vpu ; unlike old world monkey TRIM5α proteins, human TRIM5α proteins do not have anti-HIV-1 activity. These facts suggest that these host factors have imposed very strong evolutionary pressures during the cross-species transmission of HIV-1 to humans, and the virus needs to develop counteractive mechanisms in order to spread into humans. Why HIV-1 failed to develop a strategy to counteract this novel factor is an intriguing and critical question. One possibility is that it may not be broadly expressed in human tissues, particularly in the primary sites of HIV-1 replication. Among different CEM-derived cell lines, only CEM.NKR cells express this factor. In addition, previous proteomics investigation has found that CEM.NKR cells lose one cellular gene calnexin , indicating a difference in gene expression profile between CEM.NKR and its parental cell line. Consistently, our biological analyses demonstrate that CEM.NKR cells express an extra host factor. It is very fortunate that this factor exhibits very strong anti-HIV-1 activity. It will be very interesting to know whether the expression of this factor is broadly inducible in various tissues, particularly in CD4+ T cells and monocytes/macrophages. Such induction could be directly used for HIV-1 suppression. Thus, further characterization of this novel factor and study of its anti-HIV mechanism would lead to the discovery of a powerful antiretroviral treatment.
Plasmids, cell lines, and viruses
Constructions of HIV-1 proviral vectors pNL-Neo, pNL-NeoΔVif, pNL Gag, and pNLΔEnv were described before . Human APOBEC3 expression vectors pcDNA3.1-A3B and A3G and VR-A3H were described before [12, 17]. The calnexin gene with a 3' HA tag was inserted into the MuLV expression vector pMSCVneo by EcoRI/XhoI digestion to create pMSCVneo-CANX. pMSCVneo-GFP was described before . To create pNL-hVif and pNL-macVif, pNL4-3 NotI/XbaI was first generated. This plasmid contains a NotI site at the end of pol and XbaI site in front of vpr and the three ATG codons in vif overlapping with pol were silenced. After that, the vif from SIVmac and HIV-1 were then inserted by NotI/XbaI digestion to create pNL-macVif and pNL-hVif.
The HIV indicator cell line TZM-BI and human T cell lines H9, CEM-SS, CEM-T4, CEM.NKR, and A2.01 were from NIH AIDS Research and Reference Reagent Program. The CEM-SS (A3G) cell line was described before . CEM.NKR clones #1, #2, #3, #4, #5, #6, #7, and #8 were isolated by limiting dilution of CEM.NKR cells in a 96-well culture plate. The HIV-infected H9 and CEM.NKR cell lines were generated by infecting these cells with viruses from pNL-Neo or pNL-Neo Vif followed by G418 selection. CEM.NKR (GFP), CEM.NKR (CANX), CEM-T4 (CANX), and CEM-SS (CANX) cell lines were generated by infecting these cells with viruses from pMSCVneo-CANX or pMSCVneo-GFP followed by G418 selection. T cells were cultured in RPMI 1640 with 10% fetal bovine serum (HyClone). 293T and TZM-BI were cultured in DMEM with 10% bovine calf serum (HyClone).
HIV-1 or MuLV viruses were produced from 293T or Phoenix-AMPHO cells by the standard calcium phosphate transfection.
The polyclonal anti-human A3G antibody was from W. Greene through the AIDS Research and Reference Reagent Program. The mouse anti-human A3F polyclonal antibody was from Abnova, Taiwan. Other antibodies used included a polyclonal rabbit anti-actin antibody (C-11) (Santa Cruz Biotechnology), PE-conjugated mouse anti-human CXCR4 and FITC-conjugated mouse anti-human CD4 (BD Biosciences), HRP-conjugated anti-HA (Roche Applied Science), and HRP-conjugated anti-rabbit, human, or mouse IgG secondary antibodies (Pierce). Detection of the HRP-conjugated antibody was performed using Supersignal Wetpico Chemiluminescence Substrate kit (PIERCE).
HIV-1 infection of human T cell lines
A total of 2 × 105 cells were inoculated with 100 ng p24Gag of HIV-1 viruses at 37°C for three hours. After removal of the inocula followed by three times of extensive washing, cells were cultured in 24-well plates. Culture supernatants were then collected daily for measurement of p24Gag by ELISA.
Sequencing of viral genes
Total cellular DNAs were extracted from HIV-infected H9 and CEM.NKR cells by the DNeasy tissue kit (Qiagen). A 420-bp fragment was PCR-amplified by a previously described primer pair  and cloned into the pCR4-TOPO vector (Invitrogen). Multiple clones were selected and sequenced by the flanking T3 and T7 primers.
Real-time PCR measurement of viral reverse transcripts
A3DE, A3H, or GAPDH (Glyceraldehyde 3-phosphate dehydrogenase)-specific PCR primer pairs as well as an A3H-specific fluorescence-labeled probe were described previously [12, 17]. The sequence of A3DE-specific fluorescence-labeled probe is 5'-/56-FAM/CGCTCAAATCTCCTTTGGGACACAGG/36-TAMSp/-3'. Total cellular RNAs were extracted by TRIzol (Invitrogen) from different cell lines. 1 μg of total RNA was subjected to reverse transcription using Superscriptase II reverse transcriptase and oligo(dT)12–18 as a primer (Invitrogen). A3DE and A3H mRNAs were first determined by TaqMan® Master Mix gene expression kit (Applied Biosystems) and then normalized to the levels of GAPDH mRNA, which were determined by the SYBR Green® PCR Master Mix kit (Applied Biosystems).
A previously described protocol was used . Briefly, 293T cells were seeded in six-well plates at 8 × 105/well in 2 ml medium. Twelve hours later, cells were transfected with 6 μg of HIV Env expression vector pNLΔGag and washed with PBS four hours' later. Simultaneously, 8 × 105 T cells were infected with 500 ng of VSV-pseudotyped Env-defective HIV-1 from pNL Env-transfected 293T cells at 37°C for three hours. After removal of the inocula and extensive washing, infected T cells were added to the Env-expressing 293T cell culture. After 48 hours, supernatants from these co-cultures were collected to infect TZM-BI cells. Viral infectivity was finally determined by measuring cellular luciferase activities after another 48 hours.
We thank Ronald J. Patterson for critical reading of this manuscript. We thank the NIH AIDS Reagent Repository for the polyclonal anti-human A3G antibody contributed by W. Greene and human T cell lines H9, CEM-SS, CEM-T4, A2.01, and CEM.NKR. We thank G. Nolan for the Phoenix-AMPHO cell line. Y.-H.Z was supported by grants AI063944 and AI080225 from the National Institutes of Health.
- Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, McCarthy RE: Continuous Culture Of Human Lymphoblasts From Peripheral Blood Of A Child With Acute Leukemia. Cancer. 1965, 18: 522-529. 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J.View ArticlePubMedGoogle Scholar
- Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA, Sodroski J: Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol. 1992, 66 (11): 6489-6495.PubMed CentralPubMedGoogle Scholar
- von Schwedler U, Song J, Aiken C, Trono D: Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol. 1993, 67 (8): 4945-4955.PubMed CentralPubMedGoogle Scholar
- Nara PL, Hatch WC, Dunlop NM, Robey WG, Arthur LO, Gonda MA, Fischinger PJ: Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses. 1987, 3 (3): 283-302. 10.1089/aid.1987.3.283.View ArticlePubMedGoogle Scholar
- Folks T, Benn S, Rabson A, Theodore T, Hoggan MD, Martin M, Lightfoote M, Sell K: Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci USA. 1985, 82 (13): 4539-4543. 10.1073/pnas.82.13.4539.PubMed CentralView ArticlePubMedGoogle Scholar
- Howell DN, Andreotti PE, Dawson JR, Cresswell P: Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J Immunol. 1985, 134 (2): 971-976.PubMedGoogle Scholar
- Han Y, Wang X, Dang Y, Zheng YH: APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication. PLoS Pathog. 2008, 4 (7): e1000095-10.1371/journal.ppat.1000095.PubMed CentralView ArticlePubMedGoogle Scholar
- Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002, 418 (6898): 646-650. 10.1038/nature00939.View ArticlePubMedGoogle Scholar
- Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N: An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics. 2002, 79 (3): 285-296. 10.1006/geno.2002.6718.View ArticlePubMedGoogle Scholar
- Goila-Gaur R, Strebel K: HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology. 2008, 5: 51-10.1186/1742-4690-5-51.PubMed CentralView ArticlePubMedGoogle Scholar
- Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH: Cytidine Deamination of Retroviral DNA by Diverse APOBEC Proteins. Curr Biol. 2004, 14 (15): 1392-1396. 10.1016/j.cub.2004.06.057.View ArticlePubMedGoogle Scholar
- Dang Y, Wang X, Esselman WJ, Zheng YH: Identification of APOBEC3DE as Another Antiretroviral Factor from the Human APOBEC Family. J Virol. 2006, 80 (21): 10522-10533. 10.1128/JVI.01123-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Doehle BP, Schafer A, Cullen BR: Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology. 2005, 339 (2): 281-288. 10.1016/j.virol.2005.06.005.View ArticlePubMedGoogle Scholar
- Liddament MT, Brown WL, Schumacher AJ, Harris RS: APOBEC3F Properties and Hypermutation Preferences Indicate Activity against HIV-1 In Vivo. Curr Biol. 2004, 14 (15): 1385-1391. 10.1016/j.cub.2004.06.050.View ArticlePubMedGoogle Scholar
- Wiegand HL, Doehle BP, Bogerd HP, Cullen BR: A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. Embo J. 2004, 23 (12): 2451-2458. 10.1038/sj.emboj.7600246.PubMed CentralView ArticlePubMedGoogle Scholar
- Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM: Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol. 2004, 78 (11): 6073-6076. 10.1128/JVI.78.11.6073-6076.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Dang Y, Siew LM, Wang X, Han Y, Lampen R, Zheng YH: Human Cytidine Deaminase APOBEC3H Restricts HIV-1 Replication. J Biol Chem. 2008, 283 (17): 11606-11614. 10.1074/jbc.M707586200.PubMed CentralView ArticlePubMedGoogle Scholar
- Harari A, Ooms M, Mulder LC, Simon V: Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol. 2009, 83 (1): 295-303. 10.1128/JVI.01665-08.PubMed CentralView ArticlePubMedGoogle Scholar
- OhAinle M, Kerns JA, Li MM, Malik HS, Emerman M: Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe. 2008, 4 (3): 249-259. 10.1016/j.chom.2008.07.005.PubMed CentralView ArticlePubMedGoogle Scholar
- Tan L, Sarkis PT, Wang T, Tian C, Yu XF: Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. Faseb J. 2008, 23 (1): 279-287. 10.1096/fj.07-088781.View ArticlePubMedGoogle Scholar
- Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE: Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 2007, 3 (4): e63-10.1371/journal.pgen.0030063.PubMed CentralView ArticlePubMedGoogle Scholar
- OhAinle M, Kerns JA, Malik HS, Emerman M: Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J Virol. 2006, 80 (8): 3853-3862. 10.1128/JVI.80.8.3853-3862.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Dang Y, Siew LM, Zheng YH: APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated. J Biol Chem. 2008, 283 (19): 13124-13131. 10.1074/jbc.M708728200.PubMed CentralView ArticlePubMedGoogle Scholar
- Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF: Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 2003, 302 (5647): 1056-1060. 10.1126/science.1089591.View ArticlePubMedGoogle Scholar
- Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K: The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol. 2003, 77 (21): 11398-11407. 10.1128/JVI.77.21.11398-11407.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K: Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology. 2004, 1 (1): 27-10.1186/1742-4690-1-27.PubMed CentralView ArticlePubMedGoogle Scholar
- Santa-Marta M, da Silva FA, Fonseca AM, Goncalves J: HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J Biol Chem. 2005, 280 (10): 8765-8775. 10.1074/jbc.M409309200.View ArticlePubMedGoogle Scholar
- Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J: The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004, 427 (6977): 848-853. 10.1038/nature02343.View ArticlePubMedGoogle Scholar
- Neil SJ, Zang T, Bieniasz PD: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008, 451 (7177): 425-430. 10.1038/nature06553.View ArticlePubMedGoogle Scholar
- Han Y, Wang X, Dang Y, Zheng YH: Demonstration of a novel HIV-1 restriction phenotype from a human T cell line. PLoS ONE. 2008, 3 (7): e2796-10.1371/journal.pone.0002796.PubMed CentralView ArticlePubMedGoogle Scholar
- Scott JE, Dawson JR: MHC class I expression and transport in a calnexin-deficient cell line. J Immunol. 1995, 155 (1): 143-148.PubMedGoogle Scholar
- Otteken A, Moss B: Calreticulin interacts with newly synthesized human immunodeficiency virus type 1 envelope glycoprotein, suggesting a chaperone function similar to that of calnexin. J Biol Chem. 1996, 271 (1): 97-103. 10.1074/jbc.271.1.97.View ArticlePubMedGoogle Scholar
- Li Y, Bergeron JJ, Luo L, Ou WJ, Thomas DY, Kang CY: Effects of inefficient cleavage of the signal sequence of HIV-1 gp 120 on its association with calnexin, folding, and intracellular transport. Proc Natl Acad Sci USA. 1996, 93 (18): 9606-9611. 10.1073/pnas.93.18.9606.PubMed CentralView ArticlePubMedGoogle Scholar
- Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR: Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 2003, 114 (1): 21-31. 10.1016/S0092-8674(03)00515-4.View ArticlePubMedGoogle Scholar
- Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, Landau NR: APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem. 2004, 279 (51): 53379-53386. 10.1074/jbc.M408802200.View ArticlePubMedGoogle Scholar
- Zennou V, Bieniasz PD: Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology. 2006, 349 (1): 31-40. 10.1016/j.virol.2005.12.035.View ArticlePubMedGoogle Scholar
- Marin M, Rose KM, Kozak SL, Kabat D: HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med. 2003, 9 (11): 1398-1403. 10.1038/nm946.View ArticlePubMedGoogle Scholar
- Sheehy AM, Gaddis NC, Malim MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med. 2003, 9 (11): 1404-1407. 10.1038/nm945.View ArticlePubMedGoogle Scholar
- Stopak K, de Noronha C, Yonemoto W, Greene WC: HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell. 2003, 12 (3): 591-601. 10.1016/S1097-2765(03)00353-8.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.